A revolution in treatment of biliary disorders
Cellular therapy platform to repair and replace diseased tissues and organs
A leading biomedical company with expertise from the University of Cambridge
Bilitech is a bleeding edge biomedical technology company which leverages a cellular therapy platform in order to advance the huge potential of organoid technology in regenerative medicine.
The company’s technological calibre is underpinned by a sophisticated and experienced body of specialists with decades of experience in the biomedical sphere.
Dr Fotis Sampaziotis
Chief Executive Officer
Dr Kourosh Saeb-Parsy
Chief Medical Advisor
Kourosh is a liver, kidney and pancreas transplant surgeon and a research group leader at the University of Cambridge. He has extensive commercial experience and has worked at board level with multiple commercial organisations, from start-ups to multinationals. He has established several successful collaborative networks, creating synergy between clinical, academic and commercial organisations. His laboratory research interests are focused on the function, safety and immunogenicity of cellular therapies, including through the use of innovative experimental models. His clinical research is focused on improving outcomes after liver, kidney and pancreas transplantation.
Lab-grown tissue repairs human organ for first time, Cambridge University scientists reveal
Publisher The Telegraph